333 related articles for article (PubMed ID: 30336096)
21. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars: Implications for health-system pharmacists.
Lucio SD; Stevenson JG; Hoffman JM
Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
24. A Comprehensive Overview on Biosimilars.
Kadam V; Bagde S; Karpe M; Kadam V
Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
[TBL] [Abstract][Full Text] [Related]
25. Frontiers in nonclinical drug development: biosimilars.
Ryan AM
Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
[TBL] [Abstract][Full Text] [Related]
26. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
27. Current market and regulatory landscape of biosimilars.
Bhatt V
Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
[TBL] [Abstract][Full Text] [Related]
28. On safety margin for drug interchangeability.
Zheng J; Chow SC; Song F
J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
[TBL] [Abstract][Full Text] [Related]
29. [Biosimilars, no generic biologicals!].
Knuts B
J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245
[TBL] [Abstract][Full Text] [Related]
30. Biosimilars: policy, clinical, and regulatory considerations.
Gottlieb S
Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
[TBL] [Abstract][Full Text] [Related]
31. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
33. The economic implications of biosimilars.
Singh SC; Bagnato KM
Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
[TBL] [Abstract][Full Text] [Related]
34. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
35. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
36. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
37. Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
Rupert DJ; Jordan AM; Ziemian MA; Brown RM; Fleming NS; Lefebvre RC
BioDrugs; 2022 Sep; 36(5):645-655. PubMed ID: 35962911
[TBL] [Abstract][Full Text] [Related]
38. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
Feldman SR; Bagel J; Namak S
Am J Med Sci; 2018 May; 355(5):411-417. PubMed ID: 29753369
[TBL] [Abstract][Full Text] [Related]
39. Biosimilars: a regulatory perspective from America.
Kay J
Arthritis Res Ther; 2011 May; 13(3):112. PubMed ID: 21586106
[TBL] [Abstract][Full Text] [Related]
40. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
